Novo Nordisk A/S $NVO Shares Acquired by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 9.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 14,336 shares of the company’s stock after buying an additional 1,186 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Novo Nordisk A/S were worth $989,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of NVO. Verus Capital Partners LLC grew its stake in Novo Nordisk A/S by 131.0% during the second quarter. Verus Capital Partners LLC now owns 8,599 shares of the company’s stock worth $594,000 after buying an additional 4,876 shares during the period. Birchcreek Wealth Management LLC boosted its position in Novo Nordisk A/S by 82.9% during the 2nd quarter. Birchcreek Wealth Management LLC now owns 5,427 shares of the company’s stock worth $375,000 after purchasing an additional 2,460 shares during the period. Samalin Investment Counsel LLC increased its holdings in Novo Nordisk A/S by 5.6% in the 2nd quarter. Samalin Investment Counsel LLC now owns 6,979 shares of the company’s stock valued at $482,000 after purchasing an additional 372 shares in the last quarter. Vise Technologies Inc. purchased a new position in Novo Nordisk A/S in the second quarter valued at about $1,873,000. Finally, Allworth Financial LP boosted its position in shares of Novo Nordisk A/S by 28.7% in the second quarter. Allworth Financial LP now owns 39,650 shares of the company’s stock worth $2,737,000 after buying an additional 8,845 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $55.00 price target (up from $50.00) on shares of Novo Nordisk A/S in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Trading Down 2.3%

Shares of NYSE:NVO opened at $49.12 on Friday. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $112.52. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a market cap of $219.32 billion, a P/E ratio of 13.49, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a 50 day moving average of $54.69 and a 200-day moving average of $61.14.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.